Toripalimab plus chemo after NSCLC surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of lung cancer called non-small cell lung cancer (NSCLC) that was removed completely by surgery within the last 60 days.
- You either did not receive any anti-cancer treatment before surgery, or you had chemo-immunotherapy before surgery and still have cancer in your lymph nodes.
- Your cancer does not have changes (mutations) in the EGFR or ALK genes.
- You are in generally good health (ECOG performance status 0 or 1) and your organs are working well.
- You are willing to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a drug called toripalimab, given after lung cancer surgery, can help keep the cancer from coming back in people with early-stage non-small cell lung cancer. It uses a blood test (ctDNA) to look for leftover cancer cells and decide who might benefit most.
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.
This trial tests a new combination of drugs given before surgery for stage III lung cancer. It aims to shrink the tumor to make surgery more effective and possibly improve your chances of a cure.
This trial tests whether giving an immunotherapy drug called toripalimab together with chemotherapy after lung cancer surgery can help prevent small cell lung cancer from coming back. It is for people who had surgery to remove lung cancer and were found to have small cell lung cancer in the removed tissue.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy after lung cancer surgery can help stop the cancer from coming back. It is for people with non-small cell lung cancer that has not spread to the brain and does not have certain genetic changes (EGFR/ALK mutations).
Hear when a new Stage IIB-III NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.